Hypersensitivity & Autoimmunity 1of2

Overview

Robert Kellar, Ph.D. explains how adaptive immune responses can become harmful, organizing hypersensitivity into four mechanisms: IgE-mediated allergy, tissue-bound antibody reactions, circulating immune-complex deposition, and T-cell-mediated injury. Examples connect each mechanism to clinical conditions including anaphylaxis, rheumatic fever, myasthenia gravis, Graves disease, glomerulonephritis, multiple sclerosis, type 1 diabetes, and Hashimoto disease.

Key takeaways

Type I hypersensitivity is an IgE-and-mast-cell response: sensitization during an initial exposure enables rapid mediator release on later exposure, with histamine and leukotrienes contributing to allergy symptoms and airway effects.
Type II and type III hypersensitivity differ mainly by where antibodies meet antigens: type II antibodies bind antigens on target tissue, whereas type III circulating immune complexes deposit in sites such as kidneys, joints, and vessel walls.
Group A streptococcal infection can lead to type II rheumatic fever when anti-streptococcal antibodies cross-react with heart or joint tissue, potentially causing carditis and lasting cardiac scarring.
Autoantibodies can alter receptor function in opposite ways: they block acetylcholine receptors in myasthenia gravis but stimulate thyroid-stimulating hormone receptors in Graves disease.
Type IV hypersensitivity is driven by T cells rather than antibodies and includes immune injury in conditions such as multiple sclerosis, type 1 diabetes, Hashimoto disease, and contact dermatitis.
Anaphylaxis can rapidly swell laryngeal tissue and obstruct breathing; severe allergy preparedness centers on emergency treatment and access to epinephrine.

Chapters

0:00 Adaptive Immunity Review: Barriers, Memory, and Vaccines

First-line defenses include skin, mucous membranes, and other physical or chemical barriers; inflammation is part of innate defense.
Adaptive immunity uses diverse B and T lymphocytes, central and peripheral tolerance, and memory to respond to a wider variety of pathogens.
Vaccines create an initial antigen exposure that builds immune memory for a faster, stronger response on later exposure.

4:20 Hypersensitivity as Excessive, Self-Reinforcing Immune Injury

Hypersensitivity occurs when an immune response to an antigen exceeds what is appropriate and causes tissue damage, as in hives.
Responses can be triggered or maintained inappropriately and are difficult to control once underway.
The lecture frames hypersensitivity as a pathological positive-feedback loop, contrasting it with physiological loops such as blood clotting and oxytocin-driven labor.

9:10 Four Hypersensitivity Types: Antibodies, Immune Complexes, and T Cells

Type I is the IgE-associated allergic response; types II and III involve antibodies, but differ in whether antibodies bind tissue antigens or form circulating complexes.
Type II examples include incompatible blood transfusions, where ABO and Rh antigens can trigger IgG- and IgM-mediated reactions.
Type III complexes can lodge in blood vessel walls, joints, or kidneys; type IV is T-cell-mediated and includes transplant rejection.

17:50 Type I Allergy: Sensitization by B Cells and TH2 Cells

During initial exposure to an allergen such as pollen, a B cell presents antigen and activates a TH2 helper T-cell response.
B cells produce allergen-specific IgE, which binds to mast cells and sensitizes them for subsequent exposures.
On repeat exposure, allergen binding activates sensitized mast cells and drives release of inflammatory mediators.

20:26 Mast-Cell Mediators Drive Immediate and Late Allergic Reactions

Mast-cell degranulation rapidly releases histamine, proteases, and chemotactic factors, causing vasodilation, vascular leakage, and smooth-muscle contraction.
Bronchial smooth-muscle spasm can make breathing difficult, while histamine-driven blood flow and secretions contribute to watery eyes and nasal symptoms.
A later phase involves de novo synthesis from arachidonic acid, including prostaglandins and leukotrienes.

24:20 Type I Symptoms: From Hives to Anaphylaxis

Type I reactions can follow exposure to pollen, dust, pet dander, foods such as peanuts or shellfish, insect venom, or medications such as penicillin.
Mast-cell mediators and interleukin-13 contribute to tissue inflammation and mucus hypersecretion.
Anaphylaxis can cause severe laryngeal swelling and airway obstruction; the lecture emphasizes that known severe allergies warrant an emergency response plan and epinephrine access.

29:30 Type II Hypersensitivity: Tissue-Bound Antibodies and Strep Cross-Reactivity

In type II hypersensitivity, antibodies bind antigens located on cells or tissues; unlike type III, the binding occurs at the target tissue rather than in circulation.
After group A streptococcal infection, antibodies against streptococcal antigens can cross-react with similar antigens in heart tissue.
This molecular mimicry can cause inflammation affecting the myocardium, heart valves, and connective tissue.

34:00 Rheumatic Fever and Aschoff Bodies After Streptococcal Infection

Rheumatic fever can follow streptococcal infection when cross-reactive antibodies inflame the heart and joints; untreated disease may leave lasting cardiac damage.
Aschoff bodies are associated with rheumatic carditis, and chronic inflammation can scar myocardium and impair heart function.
The lecture contrasts historical risks before widespread antibiotics with the substantial reduction in severe streptococcal complications after antibiotic treatment became common.

39:57 Type II Autoantibodies: Myasthenia Gravis and Graves Disease

In myasthenia gravis, antibodies block acetylcholine receptors at the neuromuscular junction, weakening signal transmission and muscle contraction.
Weakness can affect respiratory muscles, making myasthenia gravis potentially serious rather than merely a loss of strength.
In Graves disease, stimulatory antibodies activate thyroid-stimulating hormone receptors, increasing T3 and T4 production and causing hyperthyroidism.

45:55 Type III Hypersensitivity: Immune Complexes in Kidneys, Joints, and Vessels

Type III begins when circulating antibodies bind circulating antigens to form immune complexes that can become trapped in tissues.
Common deposition sites include kidney filtration structures, synovial joints, and blood vessel walls; complement and neutrophils then drive inflammation.
The resulting conditions include glomerulonephritis, reactive arthritis, and vasculitis; systemic lupus erythematosus is also introduced as an immune-complex disease.

50:41 Type IV Hypersensitivity: CD4 and CD8 T-Cell Tissue Damage

Type IV is delayed and cell-mediated, involving CD4 helper T cells, CD8 cytotoxic T cells, and macrophages rather than antibody binding as the defining mechanism.
CD4 cells recognize antigen presented by cells such as dendritic cells or macrophages and release cytokines that recruit inflammation.
CD8 T cells can directly kill antigen-bearing target cells; transplant rejection and contact dermatitis from poison ivy or poison oak illustrate this pathway.

53:10 Type IV Disease Examples and the Transition to Autoimmunity

Multiple sclerosis involves immune injury to central nervous system myelin, while type 1 diabetes involves T-cell destruction of pancreatic beta cells that produce insulin.
Hashimoto disease destroys thyroid tissue and reduces thyroid hormone production; Graves disease differs because its antibodies stimulate the thyroid receptor.
Celiac disease is described as T-cell-mediated damage to the intestinal lining, while Crohn disease is presented as a possible type IV condition and IBS is distinguished from it.
Rheumatoid arthritis is identified as type IV, distinct from antibody-dominated reactive arthritis; the next lecture is set to continue with autoimmune disorders and HIV/AIDS.

Summary, takeaways, and chapters were generated by AI from the video's transcript and may contain errors. The video belongs to its creator, Robert Kellar, Ph.D..